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Abstract
Background: Influenza viruses evolve rapidly and undergo immune driven selection, 
especially in the hemagglutinin (HA) protein. We report amino acid changes affecting 
antigenic epitopes and receptor-binding sites of A(H3N2) viruses circulating in Kilifi, 
Kenya, from 2009 to 2017.
Methods: Next-generation sequencing (NGS) was used to generate A(H3N2) virus 
genomic data from influenza-positive specimens collected from hospital admissions 
and health facility outpatients presenting with acute respiratory illness to health fa-
cilities within the Kilifi Health and Demographic Surveillance System. Full-length HA 
sequences were utilized to characterize A(H3N2) virus genetic and antigenic changes.
Results: From 186 (90 inpatient and 96 outpatient) influenza A virus-positive speci-
mens processed, 101 A(H3N2) virus whole genomes were obtained. Among viruses 
identified in inpatient specimens from 2009 to 2015, divergence of circulating 
A(H3N2) viruses from the vaccine strains A/Perth/16/2009, A/Texas/50/2012, and 
A/Switzerland/9715293/2013 formed 6 genetic clades (A/Victoria/208/2009-like, 
3B, 3C, 3C.2a, 4, and 7). Among viruses identified in outpatient specimens from 
2015 to 2017, divergence of circulating A(H3N2) viruses from vaccine strain A/Hong 
Kong/4801/2014 formed clade 3C.2a, subclades 3C.2a2 and 3C.2a3, and subgroup 
3C.2a1b. Several amino acid substitutions were associated with the continued ge-
netic evolution of A(H3N2) strains in circulation.
Conclusions: Our results suggest continuing evolution of currently circulating 
A(H3N2) viruses in Kilifi, coastal Kenya and suggest the need for continuous genetic 
and antigenic viral surveillance of circulating seasonal influenza viruses with broad 
geographic representation to facilitate prompt and efficient selection of influenza 
strains for inclusion in future influenza vaccines.
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1  | INTRODUC TION
Seasonal influenza viruses infect 5%-15% of the global population 
annually, resulting in 290 000-650 000 deaths each year.1,2 The dis-
ease burden is highest in developing countries especially in sub-Sa-
haran Africa,3-5 where influenza viruses may circulate year-round 
without clear seasonality; this is in contrast to the clear seasonal-
ity observed in temperate climatic regions.6 Safe influenza vac-
cines exist,1 but effectiveness depends on host immune responses 
and how well the vaccine strains match the strains in circulation.7 
Vaccine effectiveness can be low when there is a mismatch between 
vaccine selected strains and circulating viruses.8
Influenza A viruses (IAV) cause the majority of influenza-associ-
ated disease burden and are further classified into subtypes based 
on the combination of their hemagglutinin (HA) and neuraminidase 
(NA) surface glycoproteins.1 IAV, especially A(H3N2) virus, evolve 
rapidly and undergo immune driven selection.9 This occurs through 
changes in viral antigenic epitopes that result in evasion of immune 
recognition and mainly involves mutations in the HA and NA gene 
segments.10,11
The HA glycoprotein is the primary target of host neutralizing 
antibodies, which inhibit the binding of HA to sialic acid recep-
tors present on epithelial cell membranes of the upper respiratory 
tract.12 Influenza A(H3N2) virus HA possesses defined antigenic 
epitopes (five sites designated A through E) and receptor-binding 
sites.13 Accumulation of mutations at these antigenic sites results 
in viral escape from the host immune response.14,15 These sequence 
drifts on the HA from accumulated mutations are observed more 
frequently in A(H3N2) virus than A(H1N1) virus.8,16 For example, 
during the 2013-14 influenza season, A(H3N2) virus clade 3C.2a 
viruses possessing a new glycosylation site in antigenic site B of 
HA emerged and predominated among circulating A(H3N2) viruses 
which led to a low or null vaccine effectiveness for that season.17-20 
As vaccine effectiveness may not be fully explained by antigenic 
analysis using the hemagglutinin inhibition (HI) assay, the availabil-
ity of high-throughput platforms to characterize HA genetic groups, 
for example, next-generation sequencing (NGS) techniques, can 
provide more timely information to evaluate protection afforded by 
vaccination.
Currently, the government of Kenya is considering recommend-
ing annual influenza vaccine for young children.21 As an influenza 
vaccination program is implemented, there will be a need to estab-
lish genetic and antigenic viral surveillance which could be used to 
assess how well the vaccine performs and inform public health deci-
sions on vaccination strategies.7
We characterized the genetic changes in A(H3N2) viruses cir-
culating in coastal Kenya using full-length HA sequences gener-
ated through next-generation sequencing (NGS) from respiratory 
specimens collected from inpatient and outpatient sentinel surveil-
lance sites in coastal Kenya from 2009 to 2017.
2  | METHODS
2.1 | Sample sources and molecular screening
The samples used in this study were collected from health facili-
ties within the Kilifi Health and Demographic Surveillance System 
(KHDSS) on the coast of Kenya.22 Non-residents and residents of 
KHDSS presenting to these facilities were included. First, 5304 na-
sopharyngeal/oropharyngeal (NP/OP) swabs were taken from child-
hood admissions under the age of 5 years with syndromic severe or 
very severe pneumonia23 collected as part of continuous viral pneu-
monia surveillance at the Kilifi County Referral Hospital (KCH) from 
January 2009 through December 2016.23 Second, 6254 NP swab 
samples were taken from outpatients of all ages presenting with 
acute respiratory illness to selected nine outpatient health facilities 
spread throughout the KHDSS between December 2015 and March 
2017. A comprehensive description of the study area and respiratory 
disease surveillance at KCH and surrounding outpatient health facili-
ties is available from previous reports.22-25 Samples were stored in 
viral transport medium (VTM) at −80°C prior to molecular screening 
and subsequent processing.24,26,27
Samples were screened for a range of respiratory viruses, in-
cluding IAV, using a multiplex (MPX) reverse transcription (RT)-PCR 
assay employing Qiagen QuantiFast multiplex RT-PCR kit (Qiagen),26 
with epidemiological surveillance results for the period 2007-12 pre-
viously reported.24 A real-time PCR cycle threshold (Ct) of <35.0 was 
used to define virus-positive samples.26
2.2 | RNA extraction and multi-segment real-time 
polymerase chain reaction
Viral nucleic acid extraction from IAV positive samples (Ct < 35.0) 
was performed using the QIAamp Viral RNA Mini Kit (Qiagen). 
Ribonucleic acid (RNA) was reverse transcribed, and the entire 
genome of influenza was amplified in a single multi-segment real-
time polymerase chain reaction (M-RTPCR) using the Uni/Inf 
primer set.28 The amplification was performed in 25 μL reactions 
containing 8 μL nuclease-free water, 12.5 μL 2X RT-PCR buffer, 
0.2 μL Uni12/Inf1 (10 μmol/L), 0.3 μL Uni12/Inf3 (10 μmol/L), 0.5 μL 
Uni13/Inf1 (10 μmol/L), 0.5 μL SuperScript III One-Step RT-PCR 
with Platinum Taq High Fidelity (Invitrogen), and 3 μL extracted 
RNA. Thermocycling conditions were as follows: 42°C for 50 min-
utes, 50°C for 10 minutes, 94°C for 2 minutes; four cycles (94°C 
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for 30 seconds, 43°C for 30 seconds and 68°C for 3 minutes and 
50 seconds) followed by 30 cycles of 94°C for 30 seconds, 57°C 
for 30 seconds, and 68°C for 3 minutes and 30 seconds (with the 
3 minutes and 30 seconds for the 68°C extension step increased by 
10 seconds per subsequent cycle after cycle 1), and a final extension 
step at 68°C for 10 minutes. Successful amplification was evaluated 
by running the products on a 2% Agarose gel and visualized on a UV 
transilluminator after staining with RedSafe Nucleic Acid Staining 
solution (iNtRON Biotechnology Inc).
2.3 | Next-generation sequencing (NGS) of influenza 
A virus
Following PCR, the amplicons were purified with 1X AMPure XP 
beads (Beckman Coulter Inc), quantified with Quant-iT dsDNA High 
Sensitivity Assay (Invitrogen), and normalized to 0.2 ng/μL. Indexed 
paired-end libraries were generated from 2.5 μL of 0.2 ng/μL am-
plicon pool using Nextera XT Sample Preparation Kit (Illumina) fol-
lowing the manufacturer's protocol. Amplified libraries were purified 
using 0.8X AMPure XP beads, quantitated using Quant-iT dsDNA 
High Sensitivity Assay (Invitrogen), and evaluated for fragment 
size in the Agilent 2100 BioAnalyzer System using the Agilent High 
Sensitivity DNA Kit (Agilent Technologies). Libraries were then di-
luted to 2 nmol/L in preparation for pooling and denaturation for 
running on the Illumina MiSeq (Illumina). Pooled libraries were 
NaOH denatured, diluted to 12.5 pmol/L and sequenced on the 
Illumina MiSeq using 2 × 250 bp paired-end reads with the MiSeq 
v2 500 cycle kit (Illumina). Five percent Phi-X (Illumina) spike-in was 
added to the libraries to increase library diversity by creating a more 
diverse set of library clusters. Low diversity libraries are common for 
amplicon pools and occur when a significant number of reads have 
similar sequences, for example, in amplicon pools.
2.4 | Bioinformatic analysis
Contiguous nucleotide sequence (contigs) assembly was carried out 
using the FLU module of the Iterative Refinement Meta-Assembler 
(IRMA),29 which performs iterative segment-level read sorting based 
on Lineage Assignment By Extended Learning (LABEL),30 and it-
eratively refines the references to optimize the final assembly based 
on the Striped Smith-Waterman (SSW) algorithm.31 IRMA quality 
control, variant calling and phasing, and assembly pipelines were all 
F I G U R E  1   Sample processing flow for KCH inpatient and KHDSS outpatient NP/OP specimens in the Kilifi County surveillance in coastal 
Kenya, 2009-17. Sequencing generated 101 and 41 influenza A(H3N2) virus and A(H1N1)pdm09 virus WGS, respectively. One hundred and 
one A(H3N2) virus full-length HA sequences were used for this report. KCH, Kilifi County Hospital; KHDSS, Kilifi Health and Demographic 
Surveillance System; NP/OP, nasopharyngeal/oropharyngeal specimen; MiSeq, Illumina MiSeq sequencer; WGS, whole-genome sequencing
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implemented in the EDGE Bioinformatics environment32 using IRMA 
default settings. All the sequence data were deposited in the Virus 
Epidemiology and Control (VEC) research group's Data Repository 
in Harvard Dataverse under the doi https ://datav erse.harva rd.edu/ 
and the Global Initiative on Sharing All Influenza Data (GISAID) 
EpiFlu™ database (https ://www.gisaid.org/) under the accessions EPI_
ISL_393682, EPI_ISL_393684-393703, EPI_ISL_393705-393709, 
EPI_ISL_393711-393723, EPI_ISL_393725-393753, EPI_ISL_393936-
393946, EPI_ISL_393949, EPI_ISL_393951-393953, EPI_ISL_393955-
393956, EPI_ISL_393960, EPI_ISL_393963, EPI_ISL_393965-393969, 
EPI_ISL_394051-394052, EPI_ISL_394107-394112.
2.5 | Phylogenetic analysis
Consensus nucleotide sequences of HA gene were aligned and 
translated into amino acids using MUSCLE program implemented 
in mega v7.0.26.33 The sequences of reference strains of known 
clades and Northern Hemisphere vaccine strains recommended by 
WHO included in the phylogenetic analysis were obtained from the 
GISAID EpiFlu™ database (https ://www.gisaid.org/). Phylogenetic 
trees were constructed with maximum likelihood (ML) and bootstrap 
analysis of 1000 replicates using the GTR + G model implemented in 
mega 7.0.26. The full-length HA sequences were used to character-
ize A(H3N2) strains into genetic clades and subclades according to 
ECDC guidelines.34,35
2.6 | Prediction of potential glycosylation sites
Potential N-linked glycosylation sites on the HA were determined 
using the NetNGlyc 1.0 server (http://www.cbs.dtu.dk/servi ces/
NetNG lyc/), in which a threshold of >0.5 suggests glycosylation.
2.7 | Ethics
Ethical clearance for the study was granted by the KEMRI-Scientific 
and Ethical Review Unit (SERU# 3103) and the University of Warwick 
Biomedical and Scientific Research Ethics Committee (BSREC# 
REGO-2015-6102). Informed consent was sought and received from 
the study participants for the study.
3  | RESULTS
3.1 | Direct sequencing of IAV from clinical 
specimens using NGS
The specimen processing flow for IAV NGS is shown in Figure 1. A 
total of 124/5304 (2.3%) and 168/6254 (2.7%) IAV positive speci-
mens were identified from the inpatient and outpatient facilities, 
TA B L E  1   Demographic and clinical characteristics of KCH 
inpatients and KHDSS outpatients
 
Outpatient Inpatient
n % n %
Age
0-11 mo 10 (15) 17 (49)
12-59 mo 20 (30) 18 (51)
6-15 y 20 (30) _ _
16-64 y 14 (22) _ _
>=65 y 2 (3) _ _
Gender
Female 33 (50) 18 (51)
Male 33 (50) 17 (49)
Cough
No 2 (3) 0 (0)
Yes 64 (97) 35 (100)
Breathing difficulty
No 52 (79) 1 (3)
Yes 14 (21) 34 (97)
Indrawing
No 61 (92) 1 (3)
Yes 5 (8) 34 (97)
Unable to feed
No 65 (98) 34 (97)
Yes 1 (2) 1 (3)
Oxygen saturation     
<90 1 (2) 5 (14)
>=90 65 (98) 30 (86)
Conscious level
Alert/Normal 65 (98) 28 (80)
Lethargic 1 (2) 3 (9)
Prostrate _ _ 3 (9)
Unconscious _ _ 1 (2)
Note: Characteristics of 35 KCH inpatients and 66 KHDSS outpatients 
for whom influenza A(H3N2) HA gene sequences were generated in 
coastal Kenya, 2009-17.
Abbreviations: KCH, Kilifi County Referral Hospital; KHDSS, Kilifi 
Health and Demographic Surveillance System.
F I G U R E  2   Phylogenetic tree of full-length HA gene segment for 35 KCH inpatient influenza A(H3N2) virus specimens collected from 
influenza surveillance in coastal Kenya, 2009-16. Specimens were collected between January 2009 and December 2016. The phylogenetic 
tree was inferred from the recommended A(H3N2) vaccine strains (A/Perth/16/2009, A/Victoria/361/2011, A/Texas/50/2012, A/
Switzerland/9715292/2013, and A/Hong Kong/4801/2014), selected genetic clade, subclade, and subgroup representative sequences, and 
inpatient clinical specimens identified in Kilifi, Kenya (2009-16). The Kilifi strains are color-coded using clade, subclade, and subgroup while 
the vaccine strains are coded using a diamond sign. Reference strains and HA2 amino acid substitution numbering are also shown
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respectively. Of the 292 IAV positive specimens identified for this 
study, 186 (63.7%) were retrieved for this study; the remainder 
were limited in quantity for RNA extraction, that is, <140 μL. Of 
these 186 specimens, 152 (81.7%) that passed pre-sequencing 
quality control checks were loaded onto the Illumina MiSeq: 80 
(52.6%) from the inpatient and 72 (47.4%) from the outpatient 
studies, respectively, with corresponding success in generating 
whole-genome sequences (WGS) for 71 (88.8%) and 71 (98.6%) 
specimens. A total of 101 (71.1%) A(H3N2) and 41 (28.9) A(H1N1)
pdm09 WGS were generated. For this report, 101 determined 
A(H3N2) virus full-length HA sequences were used: 35 from the 
KCH inpatient and 66 from the KHDSS outpatient studies, respec-
tively. The sociodemographic characteristics of these patients are 
shown in Table 1.
3.2 | Analysis of A(H3N2) virus HA gene sequences
We investigated the HA gene sequences to characterize the amino 
acid variations affecting antigenic epitopes, receptor-binding sites, 
and potential glycosylation. Full-length segment coverage of HA was 
obtained for all the A(H3N2) strains (35 KCH inpatient and 66 KHDSS 
outpatient) using NGS and sufficient sequence data was available 
to characterize them into genetic clades and subclades. Among the 
virus strains identified in hospital inpatient specimens (Figure 2), 
all the 35 A(H3N2) strains from 2009-15 diverged from the vac-
cine strains A/Perth/16/2009 (H3N2)-like virus, A/Texas/50/2012 
(H3N2)-like virus, and A/Switzerland/9715293/2013 (H3N2)-like 
virus. The A(H3N2) strains from 2009 to 2012 (23/35) diverged 
from the 2009-12 vaccine strain A/Perth/16/2009 (H3N2)-like 
virus and fell into clades A/Victoria/208/2009-like clade (3/24) 
and clades 7 (17/24), 4 (1/24), and 3B (2/24), respectively. A virus 
from 2014 diverged further and fell into the 3B clade (1/35). One 
virus from 2014 belonging to the 3C clade diverged from the 2014-
15 vaccine strain A/Texas/50/2012 (H3N2)-like virus (1/35). A 
virus from 2014 (1/35) and all the 2015 viruses (9/35) belonged to 
the 3C.2a clade and diverged from the 2015-16 vaccine strain A/
Switzerland/9715293/2013 (H3N2)-like virus. Among the virus 
strains identified in the outpatient specimens, the A(H3N2) viruses 
belonged to genetic clade 3C.2A(34/66), subclades 3C.2a2 (3/66) 
and 3C.2a3 (6/66), and subgroup 3C.2a1b (23/66) all of which 
significantly diverged from the 2016-17 vaccine strain A/Hong 
Kong/4801/2014 (H3N2)-like virus (Figure 3).
The high numbers of A(H3N2) viruses in the outpatient setting 
presented an additional opportunity to investigate the diversity of 
the virus in a rural community across multiple epidemic seasons. 
Viruses identified from the outpatient setting were sampled con-
tinuously between December 2015 and March 2017. Comparison 
of the deduced amino acid sequences of all the viruses identi-
fied in outpatient specimens to that of the vaccine strain A/Hong 
Kong/4801/2014 (H3N2)-like virus, from which all the 2015-17 
strains significantly diverged (Figure 3), showed that the 3C.2a 
strains (n = 34) differed from the vaccine strain by amino acid varia-
tions D53N + R142K + Q197R (HA1). All these strains had additional 
variations S96N + P194L (HA1). Some 3C.2a strains also possessed 
additional variations N31S (HA1; n = 10) and N121D (HA1; n = 4). 
The 3C.2a1b (n = 23) strains were defined by amino acid variations 
K92R + N121K + N171K + H311Q and I77V + G155E (HA2). Some 
strains also possessed an additional amino acid variation S144G 
(HA1; n = 7). The 3C.2a3 strains (n = 6) were defined by amino acid 
variations N121K + S144K (HA1), whereas the 3C.2a2 strains were 
defined by N121K + R261Q (HA1) variations. All the 3C.2a, 3C.2a3, 
3C.2a2, and 3C.2a1b amino acid substitutions were part of the over-
all evolution of the strains.
Importantly, there was gain of an N-linked glycosylation site in 
antigenic site B of HA due to a K160T amino acid substitution in 
all but three of the strains identified in the outpatient specimens 
(63/66; Figure 4). This substitution, which emerged in the 2013-14 
Northern Hemisphere influenza season among clade 3C.2a viruses, 
results in the glycosylation of residue 158 in antigenic site B of HA 
that is near the receptor-binding site and alters the antigenic prop-
erties of HA resulting in reduced vaccine effectiveness. This sub-
stitution was also observed in all but one of the strains identified in 
inpatient specimens (8/9) in 2015.
The receptor-binding site of A(H3N2) virus is highly conserved 
at amino acids positions 98, 136, 153, 183, 190, 194, 195, and 228 
on HA1. However, we did not observe any substitution in these con-
served positions in the Kilifi strains.
4  | DISCUSSION
In this study, we characterized the circulating A(H3N2) viruses in 
Kilifi between 2009 and 2017 using full-length HA sequences. The 
presence of several antigenic site mutations among A(H3N2) virus 
strains circulating between 2009 and 17 influenza seasons confirms 
the continuing evolution of circulating strains in Kilifi, Kenya.
Most of the amino acid variations associated with the continu-
ing evolution of A(H3N2) viruses in Kilifi, Kenya have also been 
reported in other A(H3N2) viruses isolated in Africa, for example, 
in Cameroon36 and Mozambique,37 and in Asia, for example, in 
Thailand.38 Thus, the continuing evolution of A(H3N2) in Kilifi is in 
F I G U R E  3   A maximum likelihood phylogenetic tree of the HA gene segment for 66 KHDSS outpatient influenza A(H3N2) virus specimens 
collected from influenza surveillance in coastal Kenya, 2015-17. The outpatient specimens were collected between December 2015 and 
March 2017. The phylogeny was reconstructed from the recommended A(H3N2) vaccine strains (A/Perth/16/2009, A/Victoria/361/2011, 
A/Texas/50/2012, A/Switzerland/9715292/2013, and A/Hong Kong/4801/2014), genetic clade, subclade, and subgroup sequence 
representatives, and outpatient clinical specimens identified in Kilifi, Kenya (2015-17). The Kilifi viruses are color-coded by clade, subclade 
and subgroup, while the vaccine strains are coded using a diamond sign. Reference strains and HA2 amino acid substitution numbering are 
also shown
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part due to the global circulation of the virus. Among virus strains 
identified in inpatient specimens, the 2009-12 virus strains clus-
tered with the A/Perth/16/2009 (H3N2)-like clade, while viruses 
from 2014 clustered with the A/Texas/50/2012 (H3N2)-like and 
A/Switzerland/9715293/2013 (H3N2)-like clades, respectively. 
Additionally, all the 2015 strains identified from the inpatient 
specimens clustered with the A/Hong Kong/4801/2014 (H3N2)-
like clade. Among virus strains identified in outpatient specimens 
between December 2015 and March 2017, the A(H3N2) viruses 
clustered with the A/Hong Kong/4801/2014 (H3N2)-like clade.
New antigenic variants emerge when at least one amino acid 
substitution occurs in the antigenic sites.39 The gain or loss of an N-
linked glycosylation site in antigenic sites can affect IAV virulence and 
recognition by neutralizing antibodies.40 All but four of the strains 
circulating in Kilifi, Kenya from 2015 to 17 harbored the K160T amino 
acid substitution in antigenic site B of HA. This substitution, which re-
sults in the gain of an N-linked glycosylation site, is associated with re-
duced VE for A (H3N2) viruses and has been described previously.18 
The substitution arose during the 2013-14 influenza season, and vi-
ruses with the substitution predominated among circulating A(H3N2) 
viruses.17 Taken together, these variations underscore the rapid evo-
lution of A(H3N2) viruses in circulation in Kilifi, Kenya.
Kenya is a country where influenza viruses circulate year-round 
without clear seasonality.41 Additionally, it lies on the equator 
hence classified as neither a Northern nor a Southern Hemisphere 
country. Currently, there is no influenza vaccination policy in 
Kenya, and the number of influenza vaccine doses distributed 
in the private sector is very limited and based on the Southern 
Hemisphere vaccine formulations. However, ongoing discussions 
about introduction of an influenza vaccine recommendation in 
the government may lead to a formal policy in the near future.21 
The genetic analysis, as demonstrated in this study, can assist with 
monitoring the evolution of seasonal influenza viruses. Once influ-
enza vaccination program is implemented in Kenya, monitoring ge-
netic and antigenic changes every year would track the evolution 
of the seasonal viruses.
Our study had several limitations. The samples used in our 
studies were limited to the coastal area, yet there may be a wide 
geographic variation in circulating genetic clades throughout 
Kenya that we could not capture in our study. Additionally, spe-
cific comparison with the Southern Hemisphere vaccine strain 
composition was limited by the small number of studies reporting 
on VE in the Southern Hemisphere. These studies, for example, 
reported moderate VE of influenza vaccine against medically at-
tended and hospitalized influenza during the 2013-14 influenza 
season.42
5  | CONCLUSION
The presence of several antigenic site mutations among A(H3N2) 
strains suggests marked drift of the circulating strains in Kilifi, 
Kenya. Routine influenza virus surveillance with broad geographic 
representation can facilitate prompt and efficient selection of influ-
enza strains for inclusion in future influenza vaccines.
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sequences from Kilifi KHDSS showing the K160T amino acid substitution in 63 of 66 HA gene sequences compared to the 2016-2017 
vaccine strain A/Hong Kong/4801/2014. The K160 amino acid is shown in red whereas the T160 amino acid substitution is shown in green 
at position 160 of HA1
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